Cancer

AACR: ICMgp100 tolerated, active in advanced melanoma

(HealthDay)—An affinity-enhanced T cell receptor specific for the human leukocyte antigen-A2 restricted melanoma gp 100 peptide fused to an anti-CD3 antibody fragment, IMCgp100, seems promising for advanced ...

Apr 09, 2014
popularity 5 / 5 (1) | comments 0

Developing new anti-cancer medicines

The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of a £34M investment by a European private biotech company in University research.

Apr 11, 2014
popularity 5 / 5 (1) | comments 0